{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:46:02Z","timestamp":1777477562243,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:p>Determination of von Willebrand factor activity is required for diagnosis and classification of von Willebrand disease. In addition, von Willebrand factor activity can be of prognostic relevance in several clinical entities including thromboembolic and cardiovascular disorders in which elevated activity correlates with a poor prognosis. The HaemosIL\u2122 assay (Instrumentation Laboratory GmbH, Munich, Germany) provides a new fully automated procedure for determination of von Willebrand factor activity. This assay measures binding of the von Willebrand factor to GP Ib\u03b1 of the platelet glycoprotein complex Ib-V-IX. In our study, we analyzed 300 samples including those of patients with hereditary von Willebrand disease. The results obtained with the HaemosIL\u2122 assay were compared to von Willebrand factor activities determined by established procedures. Activities determined with HaemosIL\u2122 correlated with those activities determined as ristocetin cofactor (r = 0.88, p &lt; 0.0001), collagen-binding (r = 0.93, p &lt; 0.0001), and GP Ib-binding (r = 0.91, p &lt; 0.0001). The comparability of results obtained by HaemosIL\u2122 and the GP Ib-binding ELISA were excellent ([HaemosIL\u2122] = 0.96 \u221e activity [GP Ib-binding ELISA] + 10.7), whereas activities determined by ristocetin cofactor or collagen-binding revealed more variance. Like the other assays, the HaemosIL\u2122 failed to indicate a loss of high-molecular-weight von Willebrand factor multimers. The HaemosIL\u2122 assay can replace the GP Ib-binding ELISA for the determination of von Willebrand factor activity. Advantages of this assay include accuracy of results, full automation, and, thus, broad availability. Since the assay does not predict the absence of high-molecular-weight multimers, multimeric analysis remains the procedure of choice for the differentiation of functional defects.<\/jats:p>","DOI":"10.1177\/1076029606291428","type":"journal-article","created":{"date-parts":[[2007,6,21]],"date-time":"2007-06-21T21:15:00Z","timestamp":1182460500000},"page":"305-310","source":"Crossref","is-referenced-by-count":27,"title":["Determination of von Willebrand Factor Activity: Evaluation of the HaemosIL\u2122 Assay in Comparison With Established Procedures"],"prefix":"10.1177","volume":"12","author":[{"given":"Christoph","family":"Sucker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Senft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00fcdiger E.","family":"Scharf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer B.","family":"Zotz","sequence":"additional","affiliation":[{"name":"Department of Hemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Duesseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2006,7,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00260.x"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00991.x"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780271211"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5.1276"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.80.4.334"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200309000-00001"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00295.x"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1365"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1054\/blre.1999.0116"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1080\/00313029700169365"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-27817"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029606291428","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029606291428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:59:00Z","timestamp":1777384740000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1076029606291428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1177\/1076029606291428"],"URL":"https:\/\/doi.org\/10.1177\/1076029606291428","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}